NCT06826677 - REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

January 23, 2025

Study Completion Date

January 23, 2025

Conditions

Small Cell Lung Carcinoma

Interventions

DRUG

Durvalumab

PATIENTS INCLUDED IN AN EARLY ACCESS PROGRAMME TREATED WITH DURVALUMAB IN COMBINATION WITH PLATINUM AND ETOPOSIDE AS FIRST-LINE THERAPY

Trial Locations (11)

Research Site, Bologna

Research Site, Catanzaro

Research Site, Lucca

Research Site, Napoli

Research Site, Palermo

Research Site, Pistoia

Research Site, Prato

Research Site, Roma

Research Site, Trento

Research Site, Varese

Research Site, Vimercate